Generic Firms Want Congress To Build On CARES Act To Prevent Critical Drug Shortages
Executive Summary
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.
You may also be interested in...
US FDA Supply Chain Guidance Includes More Stakeholders, More Risks Than CARES Act
Draft guidance on redundancy risk management plans layers risk-based expectations over new statutory requirements to plan more resilient supply chains for critical drugs.
Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.
Reshoring Debate Continues As COVID-19 Drives New Wave Of US Drug Shortages
As the response to another wave of COVID-19 infections continues, fill rates of critical medicines such as methylprednisolone are dropping. But experts say the answer is not to concentrate manufacturing in US facilities, which could lead to further risks if US supply is disrupted.